Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Short term Debt (2020 - 2022)

Arcturus Therapeutics Holdings' Short term Debt history spans 3 years, with the latest figure at $60.7 million for Q4 2022.

  • For Q4 2022, Short term Debt rose 169.89% year-over-year to $60.7 million; the TTM value through Dec 2022 reached $60.7 million, up 169.89%, while the annual FY2022 figure was $60.7 million, 169.89% up from the prior year.
  • Short term Debt reached $60.7 million in Q4 2022 per ARCT's latest filing, up from $27.7 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $60.7 million in Q4 2022 to a low of $1.2 million in Q4 2020.
  • Average Short term Debt over 3 years is $21.1 million, with a median of $22.5 million recorded in 2021.
  • Peak YoY movement for Short term Debt: surged 1697.92% in 2021, then soared 49.89% in 2022.
  • A 3-year view of Short term Debt shows it stood at $1.2 million in 2020, then soared by 1697.92% to $22.5 million in 2021, then soared by 169.89% to $60.7 million in 2022.
  • Per Business Quant, the three most recent readings for ARCT's Short term Debt are $60.7 million (Q4 2022), $27.7 million (Q3 2022), and $27.0 million (Q2 2022).